Dariohealth Corp Stock Price, News & Analysis

DarioHealth (NASDAQ: DRIO) reported third-quarter 2025 results: Q3 revenue $5.0M versus $7.4M a year earlier and $5.4M in Q2 2025. The company cites a strategic shift from one-time sales to high-margin ARR, reporting 60% GAAP gross margin and ~80% non-GAAP gross margin on its B2B2C channel. Dario added 45 new ARR clients year-to-date, exceeded its 2025 goal, and holds a $69M 2026 pipeline while targeting $12.4M in new business. Cash on hand was $31.9M after a $17.5M private placement; management expects cashflow breakeven in late 2026–early 2027.

DarioHealth (NASDAQ: DRIO) presented real‑world claims research at ISPOR Europe 2025 showing a pre‑post reduction in total medical costs among employer members using its multi‑condition digital health platform, with the largest effects in high‑risk populations. The retrospective analysis links Dario's integrated solution—connected devices, AI insights and human coaching—to measurable economic impact and improved population health outcomes.

The company said this is its first claims‑data publication and noted deployment across employers and health plans in the U.S. supporting diabetes, hypertension, weight, musculoskeletal and behavioral health.

DarioHealth (NASDAQ: DRIO) will report results for the third quarter ended September 30, 2025 and host a conference call and webcast on Thursday, November 13, 2025 at 8:30 a.m. ET, before the market opens.

Executives on the call: Erez Raphael (CEO), Steven Nelson (President & Chief Commercial Officer), and Chen Franco-Yehuda (CFO). Webcast and dial-in details are provided; a replay will be available through Thursday, November 27, 2025.

Dario (NASDAQ: DRIO) announced six new employer clients on Oct 13, 2025, adding tens of thousands of covered employees and expanding across manufacturing, education, advertising and professional services.

The company highlighted a value-based pricing model that ties payments to member engagement and clinical progress; 3 of 6 new contracts use this milestone-based framework. Dario cited a platform 5X ROI and ~$5,000 annual savings per user, plus 92 peer-reviewed studies supporting outcomes. New clients include a building materials employer with >6,000 U.S. employees and a public-school district with >40,000 staff.

DarioHealth (NASDAQ: DRIO) announced a strategic collaboration with OneStep on Oct 6, 2025 to integrate OneStep's FDA-listed smartphone-only clinical-grade fall risk assessment into Dario's multi-condition digital health platform. The parties signed a Memorandum of Understanding (MOU) and expect to finalize a Master Services Agreement in the coming weeks. The integration aims to identify fall risk among high-risk groups (including members with obesity and Medicare Advantage populations), improve engagement and independence, and drive measurable ROI for self-insured employers and health plans. The release cites falls as a >$50 billion annual direct medical cost and notes the US fall management market was ~$200 million in 2024, projected to exceed $300 million by 2033 (CAGR >5%).

DarioHealth (NASDAQ:DRIO), a digital health solutions provider for chronic condition management, has initiated a comprehensive strategic review following multiple unsolicited inquiries from interested parties. The company's Board has formed a Special Committee and engaged Perella Weinberg Partners as financial advisor to evaluate potential opportunities including a sale, merger, or strategic business combination.

In recent developments, Dario has completed an oversubscribed $17.5 million private placement, bringing its pro forma cash position to approximately $40 million as of Q2 2025. The company has also optimized its capital structure by converting outstanding preferred shares into common stock and equivalents, creating a more transparent equity structure.

DarioHealth (NASDAQ: DRIO), a global digital health market leader, has announced a $17.5 million private placement of common stock. The company will sell 2,713,180 shares at $6.45 per share, with the offering expected to close around September 23, 2025.

The private placement is being conducted under Section 4(a)(2) of the Securities Act and Regulation D, with the company committing to file a registration statement with the SEC for the resale of the shares. The proceeds will be used for general corporate purposes.

DarioHealth (NASDAQ: DRIO) released a shareholder update highlighting its strategic progress in the digital health market. The company's multi-condition platform addresses 5 chronic conditions including diabetes, hypertension, weight management, musculoskeletal, and behavioral health on a unified platform.

The company reported a commercial pipeline worth $67 million, supported by partnerships with TPAs and pharmacy managers representing 87 million member lives. Clinical studies demonstrate significant outcomes, including $5,000 annual payer savings per user, 23% reduction in hospitalizations, and 9% reduction in healthcare utilization.

DarioHealth (NASDAQ: DRIO) announced the successful launch of five new employer contracts, including its largest employer contract to date, covering 107,000 lives. The contracts, implemented during Q2 and Q3 2025, feature Dario's complete cardiometabolic suite.

The company's digital health solutions have demonstrated significant results: 23% reduction in hospitalizations, 9% reduction in healthcare utilization, and $5,000 reduction in employer costs per user. Clinical outcomes include a 1.4% reduction in eHbA1c for diabetes, 10% reduction in BMI for prediabetes, and 38% of users reducing blood pressure by one stage.

Dario maintains a robust pipeline of $67 million in commercial opportunities and targets approximately 40 new client signings by year-end 2025, representing a 35% increase over 2024.